Skip to content

Effects of shengmai injection combined with thymosin on cellular immune function in patients with sepsis and low immune function: a prospective, randomized, controlled trial

Effects of shengmai injection combined with thymosin on cellular immune function in patients with sepsis and low immune function: a prospective, randomized, controlled trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100043911
Enrollment
Unknown
Registered
2021-03-05
Start date
2019-01-01
Completion date
Unknown
Last updated
2021-07-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

sepsis

Interventions

Sponsors

The Ninth People's Hospital of Suzhou
Lead Sponsor

Eligibility

Sex/Gender
All
Age
50 Years to 89 Years

Inclusion criteria

Inclusion criteria: (1) Comply with the diagnostic criteria for sepsis. (2) Aged >= 18 years. (3) The absolute count of CD4+T lymphocytes in peripheral blood was < 500 cells/µL, and the total number of CD4+T lymphocytes was < 0.8 x 10^9/L. (4) Signing the Informed Consent.

Exclusion criteria

Exclusion criteria: (1) Basic diseases cannot be reversed, such as advanced malignant tumors, mental disorders, postoperative cardiopulmonary resuscitation, severe craniocerebral injury, etc. (2) Recent or long-term use of drugs that affect immune function. (3) The use of anti-rejection drugs and glucocorticoids after organ transplantation. (4) Patients with diseases related to the immune system who have not received systematic treatment. (5) Patients who give up rescue and cannot receive routine and basic vital sign support treatment.

Design outcomes

Primary

MeasureTime frame
Peripheral blood T cell subsets;

Countries

China

Contacts

Public ContactZou Han

The Ninth People's Hospital of Suzhou

zouhanhero@126.com+86 18550930003

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026